JNJ-26489112

JNJ-26489112

Identifiers
IUPAC name (S)-N-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide
CAS Number	871824-55-4  Y
PubChem CID	11616111
ChemSpider	9790860
UNII	G1TI012DLT
CompTox Dashboard (EPA)	DTXSID601031470
Chemical and physical data
Formula	C9H11ClN2O4S
Molar mass	278.71 g·mol−1
3D model (JSmol)	Interactive image
SMILES NS(=O)(=O)NC[C@H]1COC2=C(O1)C=CC(Cl)=C2
InChI InChI=1S/C9H11ClN2O4S/c10-6-1-2-8-9(3-6)15-5-7(16-8)4-12-17(11,13)14/h1-3,7,12H,4-5H2,(H2,11,13,14)/t7-/m0/s1 Key:KXSAIQPPGSSNKX-ZETCQYMHSA-N

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. ^{[1] [2] [3]} JNJ-26489112 was designed as a successor to topiramate. ^[4] It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase. ^[4]

JNJ-26489112 was studied as a treatment for major depressive disorder. ^[5] This clinical trial was terminated in 2013 due to a "sponsor portfolio decision", and no new development of JNJ-26489112 has been reported.

Its mechanism of action is unknown. ^[6]

See also

• JNJ-26990990

References

1. Trenité DK, Diprospero NA, Moyer JA, Gambale J, Pandina G, Ford L, Girgis S, Xi L, Nye J (August 2013). "Evaluation of JNJ-26489112, a Novel Antiepileptic Drug: A Placebo-Controlled, Exploratory Study". Clinical Therapeutics. 35 (8): e70. doi: 10.1016/j.clinthera.2013.07.204 .
2. Clinical trial number NCT00579384 for "A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram Response in Patients With Photosensitive Epilepsy" at ClinicalTrials.gov
3. Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, et al. (May 2014). "Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study". Epilepsy Research. 108 (4): 709–16. doi:10.1016/j.eplepsyres.2014.01.018. PMID   24560845. S2CID   25545178.
4. McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, et al. (November 2013). "Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112)". Journal of Medicinal Chemistry. 56 (22): 9019–30. doi:10.1021/jm400894u. PMC   4004761 . PMID   24205976.
5. Clinical trial number NCT01114698 for "A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder" at ClinicalTrials.gov
6. Zaccara G, Schmidt D (February 2016). "Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development". Pharmacological Research. 104: 38–48. doi:10.1016/j.phrs.2015.12.011. PMID   26689774.

Further reading

• Toxicological study of JNJ-26489112: Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, et al. (July 2014). "Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate". Regulatory Toxicology and Pharmacology. 69 (2): 187–200. doi:10.1016/j.yrtph.2014.03.005. PMID   24680767.